TY - JOUR
T1 - A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism
AU - Douam, Florian
AU - Fusil, Floriane
AU - Enguehard, Margot
AU - Dib, Linda
AU - Nadalin, Francesca
AU - Schwaller, Loïc
AU - Hrebikova, Gabriela
AU - Mancip, Jimmy
AU - Mailly, Laurent
AU - Montserret, Roland
AU - Ding, Qiang
AU - Maisse, Carine
AU - Carlot, Emilie
AU - Xu, Ke
AU - Verhoeyen, Els
AU - Baumert, Thomas F.
AU - Ploss, Alexander
AU - Carbone, Alessandra
AU - Cosset, François Loïc
AU - Lavillette, Dimitri
N1 - Funding Information:
This work was supported by grants from the French “Agence Nationale de la Recherche sur le Sida et les hépatites virales” (ANRS CSS4 AO2014-2q, to DL; www.anrs.fr), the FINOVI foundation (to DL;www.finovi.org), the CAS 100 Talents (to DL; http://sourcedb.cas.cn), Shanghai municipality 1000 Talents (to DL; http://www.1000plan.org/qrjh/channel/137), the European Research Council (ERC-2008-AdG-233130-HEPCENT, to FLC; https://erc.europa.eu), the National Institutes of Health (R01 AI079031 to AP; www.nih.gov), a Research Scholar Award from the American Cancer Society (RSG-15-048-01-MPC to AP; www.cancer.org) and a Burroughs Wellcome Fund Award for Investigators in Pathogenesis (to AP; www.bwfund.org). FD and ME were supported by a fellowship from the French Ministry of Research (MESR; www.enseignementsup-recherche.gouv.fr). QD is a recipient of a postdoctoral fellowship from the New Jersey Commission on Cancer Research (DHFS16PPC007; www.state.nj.us/health/ces/cancer-researchers/njccr.shtml). AC was supported by the MAPPING project (ANR-11-BINF-0003, Excellence Programme "Investissement d'Avenir"; www.agence-nationale-recherche.fr) and by funds from the Institut Universitaire de France (www.iufrance.fr). This work has been published under the framework of the LABEX ANR-10-LAB-28 and of the LabEx Ecofect (ANR-11-LABX-0048; www.agence-nationale-recherche.fr), and benefits from a funding from the state managed by the French National Research Agency as part of the Investments for the future program. TFB acknowledges funding of EU FP7 Hepamab (http://cordis.europa.eu) and Interreg IV-Hepato-Regio-Net (http://www.hepatoregionet.eu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We acknowledge the contribution of SFR Biosciences (UMS3444/CNRS, US8/Inserm, ENS de Lyon, UCBL) facilities the animal facility (PBES, Plateau de Biologie Experimental de la Souris, ENS de Lyon; especially J.F. Henry, N. Aguilera, J.L. Thoumas as well as G. Froment for advices and their technical help in handling mice), the Protein Science Facility (especially V. Senty-Segault at IBCP for the purification of the soluble BLd-H77 peptide) and theAniRA flow cytometry platform (Thibault Andrieu and Sebastien Dussurgey). We thank the Vectorology platform (Inserm U1089, Nantes) for the production of the adeno-uPA vector. We are grateful to Christina deCoste and John Grady of the Molecular Biology Flow Cytometry Core Facility (Princeton University) for outstanding technical support. We thank Emma Reungoat and Emilie Carlot for technical help. We are grateful to our co-workers and colleagues for their encouragements, advices and technical help.
Publisher Copyright:
© 2018 Douam et al.
PY - 2018/3
Y1 - 2018/3
N2 - Amino-acid coevolution can be referred to mutational compensatory patterns preserving the function of a protein. Viral envelope glycoproteins, which mediate entry of enveloped viruses into their host cells, are shaped by coevolution signals that confer to viruses the plasticity to evade neutralizing antibodies without altering viral entry mechanisms. The functions and structures of the two envelope glycoproteins of the Hepatitis C Virus (HCV), E1 and E2, are poorly described. Especially, how these two proteins mediate the HCV fusion process between the viral and the cell membrane remains elusive. Here, as a proof of concept, we aimed to take advantage of an original coevolution method recently developed to shed light on the HCV fusion mechanism. When first applied to the well-characterized Dengue Virus (DENV) envelope glycoproteins, coevolution analysis was able to predict important structural features and rearrangements of these viral protein complexes. When applied to HCV E1E2, computational coevolution analysis predicted that E1 and E2 refold interdependently during fusion through rearrangements of the E2 Back Layer (BL). Consistently, a soluble BL-derived polypeptide inhibited HCV infection of hepatoma cell lines, primary human hepatocytes and humanized liver mice. We showed that this polypeptide specifically inhibited HCV fusogenic rearrangements, hence supporting the critical role of this domain during HCV fusion. By combining coevolution analysis and in vitro assays, we also uncovered functionally-significant coevolving signals between E1 and E2 BL/Stem regions that govern HCV fusion, demonstrating the accuracy of our coevolution predictions. Altogether, our work shed light on important structural features of the HCV fusion mechanism and contributes to advance our functional understanding of this process. This study also provides an important proof of concept that coevolution can be employed to explore viral protein mediated-processes, and can guide the development of innovative translational strategies against challenging human-tropic viruses.
AB - Amino-acid coevolution can be referred to mutational compensatory patterns preserving the function of a protein. Viral envelope glycoproteins, which mediate entry of enveloped viruses into their host cells, are shaped by coevolution signals that confer to viruses the plasticity to evade neutralizing antibodies without altering viral entry mechanisms. The functions and structures of the two envelope glycoproteins of the Hepatitis C Virus (HCV), E1 and E2, are poorly described. Especially, how these two proteins mediate the HCV fusion process between the viral and the cell membrane remains elusive. Here, as a proof of concept, we aimed to take advantage of an original coevolution method recently developed to shed light on the HCV fusion mechanism. When first applied to the well-characterized Dengue Virus (DENV) envelope glycoproteins, coevolution analysis was able to predict important structural features and rearrangements of these viral protein complexes. When applied to HCV E1E2, computational coevolution analysis predicted that E1 and E2 refold interdependently during fusion through rearrangements of the E2 Back Layer (BL). Consistently, a soluble BL-derived polypeptide inhibited HCV infection of hepatoma cell lines, primary human hepatocytes and humanized liver mice. We showed that this polypeptide specifically inhibited HCV fusogenic rearrangements, hence supporting the critical role of this domain during HCV fusion. By combining coevolution analysis and in vitro assays, we also uncovered functionally-significant coevolving signals between E1 and E2 BL/Stem regions that govern HCV fusion, demonstrating the accuracy of our coevolution predictions. Altogether, our work shed light on important structural features of the HCV fusion mechanism and contributes to advance our functional understanding of this process. This study also provides an important proof of concept that coevolution can be employed to explore viral protein mediated-processes, and can guide the development of innovative translational strategies against challenging human-tropic viruses.
UR - http://www.scopus.com/inward/record.url?scp=85044834873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044834873&partnerID=8YFLogxK
U2 - 10.1371/journal.ppat.1006908
DO - 10.1371/journal.ppat.1006908
M3 - Article
C2 - 29505618
AN - SCOPUS:85044834873
SN - 1553-7366
VL - 14
JO - PLoS Pathogens
JF - PLoS Pathogens
IS - 3
M1 - e1006908
ER -